Pfizer (PFE) Profit After Tax (2009 - 2026)

Pfizer has disclosed Profit After Tax across 18 years of filings, most recently posting $2.7 billion for Q1 2026.

• In Q1 2026, Profit After Tax fell 8.7% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $7.5 billion (down 28.9% YoY), while the FY2025 annual figure was $7.8 billion, down 3.04% from the prior year.
• Profit After Tax improved to $2.7 billion in Q1 2026, from -$1.6 billion in the prior quarter.
• Over the last five years, Profit After Tax for PFE reached as high as $9.9 billion in Q3 2022 and fell as low as -$2.4 billion in Q4 2023.
• The 5-year median for Profit After Tax is $2.8 billion (2025), against an average of $2.7 billion.
• Annual changes were most pronounced in 2023 — Profit After Tax sank 127.55% — and 2025, when it soared 6997.56%.
• A 5-year view of Profit After Tax shows it stood at $225.0 million in 2022, then sank by 73.33% to $60.0 million in 2023, then jumped by 7341.67% to $4.5 billion in 2024, then slumped by 136.55% to -$1.6 billion in 2025, then surged by 265.99% to $2.7 billion in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $2.7 billion, -$1.6 billion, and $3.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.